Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "We ...
We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...
We recently published a list of 10 AI News Making Waves on Wall Street. In this article, we are going to take a look at where ...
We recently published a list of 13 Stocks Jim Cramer Recently Talked About. In this article, we are going to take a look at ...
Sales teams often struggle with streamlining their efforts to enhance productivity and close more deals. With the advancement of CRM technology, integrating ...
19hon MSN
For Q1 2025, BlackLine projects revenue between $166M and $168M and non-GAAP operating margin of 16.5%-17.5%. Full-year 2025 revenue guidance stands at $699M to $705M, reflecting 7%-8% growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback